United Therapeutics Corp (UTHR)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 1,400
- Market Cap
- $26.2B
About United Therapeutics Corp
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
SentiSense also tracks daily options readings for United Therapeutics Corp: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
United Therapeutics Corp stock analysis, sentiment tracking, and market intelligence on SentiSense.